Polyestradiol phosphate/medroxyprogesterone acetate

Polyestradiol phosphate /
medroxyprogesterone acetate
	Polyestradiol phosphate (top) and; medroxyprogesterone acetate (bottom)
Combination of
Polyestradiol phosphate	Estrogen
Medroxyprogesterone acetate	Progestogen
Clinical data
Other names	PEP/MPA
Routes of; administration	Intramuscular injection

Polyestradiol phosphate/medroxyprogesterone acetate (PEP/MPA) is a combination of polyestradiol phosphate (PEP), an estrogen, and medroxyprogesterone acetate (MPA), a progestin, which was studied in the 1960s as a long-lasting combined injectable contraceptive for women but was never marketed.^[1]^[2]^[3] It was administered by intramuscular injection once every 3 months and contained 40 mg PEP and 150 mg MPA.^[1]^[2]^[3] The combination was studied in a sample of 99 premenopausal women and was found to be effective in preventing pregnancy, but caused menstrual irregularities similar to those of MPA alone as a progestogen-only injectable contraceptive.^[1]^[2]^[3] PEP was included in the formulation to prevent estrogen deficiency and reduce menstrual abnormalities caused by MPA during long-term contraceptive therapy.^[2]

References

^ ^a ^b ^c Joseph William Goldzieher; Kenneth Fotherby (1994). Pharmacology of the contraceptive steroids. Raven Press. p. 154. ISBN 978-0-7817-0097-9.
^ ^a ^b ^c ^d Zañartu J, Rice-Wray E, Goldzieher JW (October 1966). "Fertility control with long-acting injectable steroids. A preliminary report". Obstet Gynecol. 28 (4): 513–5. PMID 5925038.
^ ^a ^b ^c Harry Beckman (1967). The Year Book of Drug Therapy. Year Book Publishers.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.